ArticleBritish journal of cancer2023

Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors.

Anthony B El-Khoueiry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.